Home > Dermatology > EADV 2019 > Late-Breaking News > Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata

Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata

Expert
Dr James Cassella
Conference
EADV 2019

The Janus kinase (JAK) inhibitor CTP-543 showed promising results in patients with moderate-to-severe alopecia areata according to interim results from a phase 2a study [1].

Alopecia areata is a poorly treatable autoimmune disease that affects women, men, and children of all ages. This chronic condition has a remarkable negative impact on quality of life and is associated with anxiety, depression, and other autoimmune conditions.

CTP-543 inhibits both JAK1 and JAK2 and is a modified version of the JAK inhibitor ruxolitinib, currently approved for the treatment of myelofibrosis and polycythemia vera. The double-blind, randomised, placebo-controlled, dose-ranging, phase 2 trial included 149 adult patients with moderate-to-severe alopecia areata. Entry criterion was an at least 50% hair loss as measured by Severity of Alopecia Tool (SALT) score. Patients were randomised to receive 4, 8, or 12 mg CTP-543 or placebo twice daily. Primary efficacy endpoint...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on